Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA First: Fees To Support Device Center Staff

Executive Summary

To enhance combination product reviews, drug fee revenue will pay for related positions in CDRH.


Related Content

User Fee Draft Suggests Congressional Wariness Of Trump Budget
US FDA May Find Relief From Trump's Hiring Freeze
FDA's Combo Products Review Transformation Begins
Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
Will Combination Products Join The User Fee Family?
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
Industry, FDA Agree On Draft User Fee Commitment Letter


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts